Growth Hormone for Osteoporosis Pseudoglioma Syndrome



Status:Withdrawn
Conditions:Osteoporosis, Ocular, Orthopedic
Therapuetic Areas:Ophthalmology, Rheumatology, Orthopedics / Podiatry
Healthy:No
Age Range:4 - Any
Updated:4/22/2017
Start Date:December 2013
End Date:December 2015

Use our guide to learn which trials are right for you!

Trial of Growth Hormone for Osteoporosis Pseudoglioma Syndrome

Osteoporosis pseudoglioma (OPPG) syndrome is a rare autosomal recessive condition of
childhood osteoporosis and congenital blindness for which new treatments are needed. We have
found that body fat is increased in OPPG and muscle mass is reduced. We hypothesize that
growth hormone therapy will improve muscle mass and bone strength in OPPG.

Osteoporosis pseudoglioma (OPPG) syndrome is a rare autosomal recessive condition of
childhood osteoporosis and congenital blindness for which new treatments are needed. We have
found that body fat is increased in OPPG and muscle mass is reduced. We hypothesize that
growth hormone therapy will improve muscle mass and bone strength in OPPG.

Inclusion Criteria:

- Osteoporosis pseudoglioma syndrome

- Age 4 years and above

- not on medication for osteoporosis

Exclusion Criteria:

- pregnant

- Age under 4 yrs

- Active malignancy
We found this trial at
1
site
655 West Baltimore Street
Baltimore, Maryland 21201
(410) 706-7410
University of Maryland School of Medicine Established in 1807, The School of Medicine is the...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials